Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

Nir Drayman, Krysten A Jones, Sarra-Anne Azizi, Heather M Froggatt, Kemin Tan, Natalia Ivanova Maltseva, Siquan Chen, Vlad Nicolaescu, Steve Dvorkin, Kevin Furlong, Rahul S Kathayat, Mason R Firpo, Vincent Mastrodomenico, Emily A Bruce, Madaline M Schmidt, Robert Jedrzejczak, Miguel A Munoz-Alia, Brooke Schuster, Vishnu Nair, Jason W BottenChristopher B Brooke, Susan C Baker, Bryan C Mounce, Nicholas S Heaton, Bryan C Dickinson, Andrzej Jaochimiak, Glenn Randall, Savaş Tay

Research output: Working paper


There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold and is a relative of SARS-CoV-2, and identified 108 effective drugs. We further evaluated the top 26 hits and determined their ability to inhibit SARS-CoV-2, as well as other pathogenic RNA viruses. 20 of the 26 drugs significantly inhibited SARS-CoV-2 replication in human lung cells (A549 epithelial cell line), with EC50 values ranging from 0.1 to 8 micromolar. We investigated the mechanism of action for these and found that masitinib, a drug originally developed as a tyrosine-kinase inhibitor for cancer treatment, strongly inhibited the activity of the SARS-CoV-2 main protease 3CLpro. X-ray crystallography revealed that masitinib directly binds to the active site of 3CLpro, thereby blocking its enzymatic activity. Mastinib also inhibited the related viral protease of picornaviruses and blocked picornaviruses replication. Thus, our results show that masitinib has broad anti-viral activity against two distinct beta-coronaviruses and multiple picornaviruses that cause human disease and is a strong candidate for clinical trials to treat SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.
Original languageEnglish (US)
PublisherCold Spring Harbor Laboratory Press
Number of pages32
StateIn preparation - Sep 1 2020

Publication series

PublisherCold Spring Harbor Laboratory Press


  • Coronavirus
  • COVID-19
  • severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Novel coronavirus
  • 2019-nCoV
  • Pandemic


Dive into the research topics of 'Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro'. Together they form a unique fingerprint.

Cite this